Atara Biotherapeutics Inc
NASDAQ:ATRA

Watchlist Manager
Atara Biotherapeutics Inc Logo
Atara Biotherapeutics Inc
NASDAQ:ATRA
Watchlist
Price: 7.8 USD Market Closed
Market Cap: 46.5m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ATRA stock under the Base Case scenario is 69.55 USD. Compared to the current market price of 7.8 USD, Atara Biotherapeutics Inc is Undervalued by 89%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ATRA Relative Value
Base Case
69.55 USD
Undervaluation 89%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.2
P/S
P/S
Price to Sales
0.2
vs History
76
vs Industry
92
Median 3Y
93.7
Median 5Y
93.7
Industry
6.9
Forward
1.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-11.1
Median 5Y
-38.4
Industry
23
Forward
-1.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-16.1
Median 5Y
-42.1
Industry
19.7
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-15.9
Median 5Y
-40.7
Industry
22.8
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
70
Median 3Y
-0.4
Median 5Y
62.1
Industry
2.6
More Details
0.4
EV/S
EV/S
Enterprise Value to Sales
0.4
vs History
71
vs Industry
80
Median 3Y
89.1
Median 5Y
89.1
Industry
7.4
Forward
2.1
More Details
0.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
0.5
vs History
19
vs Industry
79
Median 3Y
-207.6
Median 5Y
0
Industry
9.3
More Details
11.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
11.5
vs History
0
vs Industry
27
Median 3Y
-10.8
Median 5Y
-34
Industry
4.1
Forward
-4
More Details
83
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
83
vs History
0
vs Industry
25
Median 3Y
-10.7
Median 5Y
-33.3
Industry
4.1
Forward
-1.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
27
Median 3Y
-15.2
Median 5Y
-41.1
Industry
4.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
24
Median 3Y
-15.1
Median 5Y
-39.4
Industry
3.6
More Details
1.6
EV/IC
EV/IC
Enterprise Value to IC
1.6
vs History
71
vs Industry
63
Median 3Y
37.3
Median 5Y
95.2
Industry
4.7
More Details

Multiples Across Competitors

ATRA Competitors Multiples
Atara Biotherapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Atara Biotherapeutics Inc
NASDAQ:ATRA
46.2m USD 0.2 -3 11.5 83
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 901 062 -165 879.6 -201 430.7 -199 132.1
US
Abbvie Inc
NYSE:ABBV
328.7B USD 5.7 79.1 15.1 22.3
US
Amgen Inc
NASDAQ:AMGN
155B USD 4.5 26.1 14.1 23.3
US
Gilead Sciences Inc
NASDAQ:GILD
137B USD 4.8 23 10 13.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.6B USD 10.2 -114.9 24.4 25.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 018.5 -515.1 -560.9 -545.9
AU
CSL Ltd
ASX:CSL
119.9B AUD 5.1 28.1 17.3 21.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
53B USD 3.8 11.8 10.4 11.7
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.6 -64.2 -57.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
39.7B USD 16.9 -147.2 -658.7 -330.1
P/E Multiple
Earnings Growth PEG
US
Atara Biotherapeutics Inc
NASDAQ:ATRA
Average P/E: 33.6
Negative Multiple: -3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 879.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
79.1
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -114.9 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -515.1 N/A N/A
AU
CSL Ltd
ASX:CSL
28.1
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
7%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -147.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Atara Biotherapeutics Inc
NASDAQ:ATRA
Average EV/EBITDA: 14.7
11.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 430.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.1
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.1
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.9 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.4
11%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -658.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Atara Biotherapeutics Inc
NASDAQ:ATRA
Average EV/EBIT: 28.8
83
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 132.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.3
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -545.9 N/A N/A
AU
CSL Ltd
ASX:CSL
21.7
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.7
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -330.1 N/A N/A

See Also

Summary
ATRA intrinsic value, competitors valuation, and company profile.
DCF Valuation
ATRA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ATRA stock valuation using valuation multiples.
Wall Street Estimates
ATRA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ATRA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 258,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.